Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||2 February 2010|
|PDF File Size:||17.18 Mb|
|ePub File Size:||13.77 Mb|
|Price:||Free* [*Free Regsitration Required]|
Subscribe to free Drugs. El nivel de EPO en plasma previo a la dosis se sustrajo de todos los niveles que se obtuvieron tras administrarla.
Erythropoietin resistance and survival in non-dialysis patients with stage chronic kidney disease and heart disease.
Basal plasma Epo concentration in BEN patients ranged between 7.
Eritropoyetina Humana Recombinante –
Recent studies were largely devoted to the pharmacokinetics of new ESAs 10,12,14 and were usually carried out in healthy persons. For pharmacokinetic analysis the predose plasma level of Epo was subtracted from all postdose levels of Epo for each patient. Endemic Balkan Nephropathy, Proc. Renal Injury from Drugs and Chemicals, third edition.
Clin J Am Soc Nephrol ;1: The dose of beta-Epo was adjusted to attain the hemoglobin target range defined by European best practice guidelines for the management of anemia in patients with chronic renal failure A number of pharmacokinetic studies of ESA have been published, but comparison between them is difficult due to numerous methodological differences.
Eritropoyetina Humana Recombinante Delta
Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis.
These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization.
Pavlovic-Kentera V, Djukanovic Lj. Beta-erythropoietin administration and blood sampling. Subscribe to receive email notifications whenever new articles are published. As the main organs involved in Epo elimination are the kidneys and bone marrow and both kidney function and bone marrow cellularity decrease with age, the authors suggested that age and creatinine influence Epo elimination.
Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. BEN is a slow progressive chronic kidney disease and patients who progress to end-stage renal disease usually start hemodialysis in the seventh decade of life.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. The Ethics Committee of the Clinical Center of Serbia evaluated and approved the study and the participants gave informed consent.
A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection. Renal function, protein excretion and pathology of Balkan endemic nephropathy. Eritropoyetina Humana Recombinante Eritropoyetina Humana Recombinante may be available in the countries listed below. Also, the difference in other pharmacokinetic parameters presented in Table 3 remained insignificant after adjustment.
On the other hand, residual renal function was maintained longer in BEN patients than in those with other kidney diseases 34 and our BEN patients were shorter on hemodialysis treatment than non-BEN patients.
N Engl J Med ; The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test. Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases non-BEN. Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Eritropoyetina Humana Recombinante
Res Commun Mol Pathol Pharmacol ; Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein NESP. Erktropoyetina clicking Subscribe, I agree to the Drugs.
Anaemia in Balkan endemic nephropathy. The authors declare that they have no conflicts of interest related to the contents of this article.
It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. To view content sources and attributions, please refer to our editorial policy. This finding needs to be confirmed in a well-controlled study with a larger sample size. The results were expressed as mean values with standard deviations. Our patients had eeitropoyetina reserves above eritropoyehina upper limit of normal and a similar proportion of subjects from each group used iron supplements.
Colombia Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Population pharmacokinetics of darbepoetin alfa in healthy subjects.
It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Nephrol Dial Transplant ;19 Suppl 2: C reactive protein; Epo: Their main characteristics recombinantw presented in Table 1.
We recently showed that BEN hemodialysis patients required a higher dose of recombinant human erythropoietin for maintaining the target hemoglobin level than patients with other kidney diseases. In addition, iron status was assessed and supplementary iron given according to the same guidelines. The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver.
We comply with the HONcode standard for trustworthy health information – verify here. By clicking Subscribe, I agree to the Drugs.
Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.
Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. The aim of this study was to compare the pharmacokinetics of beta-erythropoietin beta-Epo given subcutaneously to BEN patients and eritropoyetiina with other kidney diseases non-BEN and to evaluate the factors influencing beta-Epo kinetics.
To view content sources and attributions, please refer to our editorial policy.